<DOC>
	<DOCNO>NCT00574496</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine , mycophenolate mofetil , methotrexate transplant may stop happen . PURPOSE : This phase II trial study well combination chemotherapy follow donor stem cell transplant work treat patient relapse high-risk primary refractory Hodgkin lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Donor Stem Cell Transplant Treating Patients With Relapsed High-Risk Primary Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>OUTLINE : Patients stratify accord response prior therapy risk factor ( presence 3 risk factor fail primary therapy primary progressive disease vs. patient relapse 100 day autologous stem cell transplant ) . - Salvage chemotherapy ( IGV MOPP ) : Patients previously receive mechlorethamine hydrochloride receive IGV ; patient previously receive gemcitabine-based regimen receive MOPP . - IGV ( ifosfamide , gemcitabine hydrochloride , vinorelbine ditartrate ) : Patients receive IGV combination chemotherapy comprise ifosfamide IV day 1-4 , gemcitabine hydrochloride IV day 1 4 , vinorelbine ditartrate IV day 1 . Treatment repeat every 2-3 week 2-3 course absence disease progression unacceptable toxicity . - MOPP ( mechlorethamine hydrochloride , vincristine , procarbazine hydrochloride , prednisone ) : Patients receive MOPP combination chemotherapy comprise mechlorethamine hydrochloride IV day 1 8 , vincristine IV day 1 8 , oral procarbazine hydrochloride day 1-14 , oral prednisone day 1-14 . Treatment repeat every 4 week least 2 course absence disease progression unacceptable toxicity . Patients progression disease salvage chemotherapy ( allograft work-up ) proceed allogeneic hematopoietic stem cell transplantation [ AHSCT ] * within 60 day completion salvage chemotherapy . NOTE : *Patients nodal mass &gt; 5 cm ben previously irradiate absence extranodal disease may undergo involved-field radiotherapy twice daily 2 week , prior AHSCT . - AHSCT reduced-intensity non-myeloablative conditioning : Patients achieve partial response stable disease salvage therapy receive fludarabine phosphate IV 30 minute day -6 -2 ; melphalan IV 15 minute day -6 -5 ; undergo AHSCT day 0 ( reduced-intensity conditioning ) . Patients achieve complete response salvage therapy receive fludarabine phosphate IV 30 minute day -6 -2 ; cyclophosphamide IV 15 minute day -6 ; total-body irradiation 20-30 minute day -1 ; undergo AHSCT day 0 ( non-myeloablative conditioning ) . - Graft-vs-host disease prophylaxis : Patients related unrelated donor receive cyclosporine IV 2-4 hour orally day -3 100 follow taper , mycophenolate mofetil IV orally day -3 46 follow taper , methotrexate IV day 1 , 3 , 6 , 11 . Patients receive umbilical cord blood receive cyclosporine mycophenolate mofetil ( methotrexate ) . Follow-up period 2 year post-transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm classical Hodgkin lymphoma , include CD20+ disease No lymphocyte predominant histology Primary refractory relapse disease 3 risk factor , fail platinumbased chemotherapy , disease relapse 100 day autologous stem cell transplantation , proven biopsy fineneedle aspiration ( cytology ) involve site Risk factor define Bsymptoms , extranodal sit disease , disease remission last &lt; 1 year firstline therapy Failed doxorubicin hydrochloride mechlorethamine hydrochloridecontaining frontline therapy Fludeoxyglucose F 18PET scan demonstrate PETavid disease No 2 prior salvage chemotherapy regimen ( patient proceed allogeneic hematopoietic stem cell transplantation [ AHSCT ] ) Donor available meeting 1 follow criterion ( patient proceed AHSCT ) : HLAmatched one allele mismatch related donor Genotypically phenotypically match ≥ 9/10 A , B , C , DRB1 , DQB1 locus , test high resolution Peripheral blood stem cell ( PBSC ) collect HLAmatched unrelated donor Matched ≥ 9/10 ( allele mismatch ) A , B , C , DRB1 , DQB1 locus , test high resolution PBSC bone marrow collect Umbilical cord blood ( 2 unit ) must ≥ 4/6 HLAA , B antigen , DRB1 allele match recipient PATIENT CHARACTERISTICS : Platelet count &gt; 50,000/mm^3 ANC &gt; 1,000/mm^3 Cardiac ejection fraction &gt; 50 % ( patient ≥ 18 year age ) Fractional shorten &gt; 50 % echocardiogram* ( patient &lt; 18 year age ) Adjusted diffuse capacity &gt; 50 % pulmonary function testing* Serum creatinine &lt; 1.5 mg/dL Creatinine clearance ≥ 50 mL/min Total bilirubin &lt; 2.0 mg/dL absence history Gilbert disease HIV I II negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Karnofsky performance status ( PS ) ≥ 70 % Lansky PS ≥ 70 % ( patient proceed AHSCT ) No active uncontrolled infection time transplantation include active infection Aspergillus mold ( patient proceed AHSCT ) NOTE : *measured since last chemotherapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior allogeneic transplantation No 1 prior autologous transplantation No inability complete plan cytoreduction due therapy complication</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
</DOC>